Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
NCT05727839
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
19
Enrollment
INDUSTRY
Sponsor class
Conditions
Cutaneous Tumor
Malignant Solid Tumor
Interventions
DRUG:
JCXH-211 Injection
Sponsor
Immorna Biotherapeutics, Inc.